AP2034A - Oxidized proteins, their biological activity, and therapeutic and diagnostic measures, which are derived from the active mechanism, from the use of these proteins or from the inhibition thereof. - Google Patents

Oxidized proteins, their biological activity, and therapeutic and diagnostic measures, which are derived from the active mechanism, from the use of these proteins or from the inhibition thereof.

Info

Publication number
AP2034A
AP2034A APAP/P/2003/002795A AP2003002795A AP2034A AP 2034 A AP2034 A AP 2034A AP 2003002795 A AP2003002795 A AP 2003002795A AP 2034 A AP2034 A AP 2034A
Authority
AP
ARIPO
Prior art keywords
proteins
inhibition
therapeutic
derived
biological activity
Prior art date
Application number
APAP/P/2003/002795A
Other versions
AP2003002795A0 (en
Inventor
Beate Kehrel
Martin Brodde
Original Assignee
Hamburger Stiftung Zur Forderung Wissenschaft
Mera Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10051983A external-priority patent/DE10051983A1/en
Priority claimed from DE2001148624 external-priority patent/DE10148624A1/en
Application filed by Hamburger Stiftung Zur Forderung Wissenschaft, Mera Gmbh filed Critical Hamburger Stiftung Zur Forderung Wissenschaft
Publication of AP2003002795A0 publication Critical patent/AP2003002795A0/en
Application granted granted Critical
Publication of AP2034A publication Critical patent/AP2034A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • AIDS & HIV (AREA)
  • Urology & Nephrology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)

Abstract

The present invention relates to substances, that inhibit the binding of oxidized proteins to CD36 or that inhibit the functions of CD36 induced by the interaction of CD36 with oxidized proteins, and their use as a medicament for humans and animals.
APAP/P/2003/002795A 2000-10-20 2001-10-19 Oxidized proteins, their biological activity, and therapeutic and diagnostic measures, which are derived from the active mechanism, from the use of these proteins or from the inhibition thereof. AP2034A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10051983A DE10051983A1 (en) 2000-10-20 2000-10-20 Medicaments useful e.g. for preventing thrombosis, inhibiting transplant rejection or treating chronic inflammatory reactions comprises agents inhibiting binding of oxidized proteins to CD36,
DE2001148624 DE10148624A1 (en) 2001-10-02 2001-10-02 Medicaments useful e.g. for preventing thrombosis, inhibiting transplant rejection or treating chronic inflammatory reactions comprises agents inhibiting binding of oxidized proteins to CD36,
PCT/EP2001/012129 WO2002032445A2 (en) 2000-10-20 2001-10-19 Inhibition of the interaction between oxidized proteins and cd36 or the active mechanism thereof

Publications (2)

Publication Number Publication Date
AP2003002795A0 AP2003002795A0 (en) 2003-06-30
AP2034A true AP2034A (en) 2009-08-28

Family

ID=26007431

Family Applications (2)

Application Number Title Priority Date Filing Date
APAP/P/2003/002795A AP2034A (en) 2000-10-20 2001-10-19 Oxidized proteins, their biological activity, and therapeutic and diagnostic measures, which are derived from the active mechanism, from the use of these proteins or from the inhibition thereof.
AP2009004857A AP2781A (en) 2000-10-20 2001-10-19 Oxidized proteins, their biological activity, and therapeutic and diagnostic measures, which are derived from the active mechansim, from the use of these porteins or from the inhibition thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
AP2009004857A AP2781A (en) 2000-10-20 2001-10-19 Oxidized proteins, their biological activity, and therapeutic and diagnostic measures, which are derived from the active mechansim, from the use of these porteins or from the inhibition thereof

Country Status (14)

Country Link
EP (2) EP1328289B1 (en)
JP (1) JP4881535B2 (en)
AP (2) AP2034A (en)
AT (1) ATE406908T1 (en)
AU (1) AU2002215032A1 (en)
CA (1) CA2453140C (en)
CY (1) CY1110418T1 (en)
DE (1) DE50114289D1 (en)
DK (1) DK1328289T3 (en)
ES (1) ES2307662T3 (en)
HK (1) HK1057857A1 (en)
OA (1) OA12431A (en)
PT (1) PT1328289E (en)
WO (1) WO2002032445A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2375601T3 (en) * 2003-04-25 2012-03-02 Hamburger Stiftung Zur Förderung Von Wissenschaft Und Kultur FIGHT AGAINST INFECTIONS BY IH VIRUSES WITH BLOOD PLASMA OXIDIZED HUMAN NEO WITH HYPOCLOROUS ACID.
EP3725324A1 (en) * 2005-09-16 2020-10-21 Cornell Research Foundation, Inc. Aromatic-cationic peptide for use in a method for reducing cd36 expression
JP2010235447A (en) * 2007-07-30 2010-10-21 Igaku Seibutsugaku Kenkyusho:Kk Inhibitory agent for inflammatory cytokine
DE102010043733A1 (en) 2010-11-10 2012-05-10 Oxprotect Gmbh Unloaded PEGylated liposomes for use as medicaments for the prophylaxis and therapy of hemorrhagic and thromboembolic disorders
DE102011003936A1 (en) 2011-02-10 2012-08-16 Oxprotect Gmbh Use of proteins / peptides that bind to GRP78 (BIP) in laboratory methods for monitoring platelet aggregation inhibitors
DE102011003944A1 (en) 2011-02-10 2012-08-16 Oxprotect Gmbh Detection and removal of misfolded proteins / peptides
US10531655B2 (en) 2011-12-02 2020-01-14 The Regents Of The University Of California Reperfusion protection solution and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991010684A1 (en) * 1990-01-08 1991-07-25 Schering Corporation Oxidized variants of gm-csf

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3819923A1 (en) * 1988-06-11 1989-12-21 Behringwerke Ag FIBRINE (OGEN) DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE
BR9007725A (en) * 1989-10-06 1992-08-18 Beth Israel Hospital METHOD FOR THE PREPARATION OF OXIDIZED LIPOPROTEINS, METHOD FOR THE PREPARATION OF LOW DENSITY OXIDATED LIPOPROTEINS, COMPOSITION OF LOW DENSITY OXIDATED LIPOPROTEIN AND APPLIANCE FOR LIPOPROTEIN OXIDATION
US5192264A (en) * 1989-10-06 1993-03-09 The Beth Israel Hospital Association Methods and apparatus for treating disease states using oxidized lipoproteins
CA2086921A1 (en) * 1990-07-18 1992-01-19 Eric T. Fossel Method for treating viral infections using oxidized lipoproteins
CA2176005A1 (en) 1993-11-08 1995-05-18 Trevor G. Redgrave Labelled diagnostic compositions and methods of their use
RU2089179C1 (en) * 1995-12-14 1997-09-10 Закрытое акционерное общество "ВАМ" Stimulator of cytokin and hemopoietic factors production and a method of its using
NZ502369A (en) 1997-06-20 2001-11-30 Leuven Res & Dev Vzw Antibodies for malondialdehyde low density lipoproteins and oxidised low density lipoproteins for detection of arterial diseases such as atherosclerosis
GB9806632D0 (en) * 1998-03-28 1998-05-27 Stevenson Robert Peptide factor
WO2000028072A1 (en) * 1998-11-06 2000-05-18 Emory University Biomarkers for oxidative stress
DE10045047A1 (en) * 2000-09-12 2002-03-21 Beate Kehrel Medicament containing activated antithrombin III

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991010684A1 (en) * 1990-01-08 1991-07-25 Schering Corporation Oxidized variants of gm-csf

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DAWSON DAVID W et al *

Also Published As

Publication number Publication date
CA2453140C (en) 2016-01-05
AP2003002795A0 (en) 2003-06-30
WO2002032445A2 (en) 2002-04-25
AP2781A (en) 2013-10-31
CY1110418T1 (en) 2015-04-29
EP1994941A3 (en) 2012-07-25
AP2009004857A0 (en) 2009-06-30
ATE406908T1 (en) 2008-09-15
WO2002032445A3 (en) 2003-04-17
AU2002215032A1 (en) 2002-04-29
JP4881535B2 (en) 2012-02-22
DK1328289T3 (en) 2008-12-15
EP1328289B1 (en) 2008-09-03
CA2453140A1 (en) 2002-04-25
ES2307662T3 (en) 2008-12-01
HK1057857A1 (en) 2004-04-23
DE50114289D1 (en) 2008-10-16
PT1328289E (en) 2008-12-10
EP1994941A2 (en) 2008-11-26
JP2004511526A (en) 2004-04-15
OA12431A (en) 2006-04-19
EP1328289A2 (en) 2003-07-23

Similar Documents

Publication Publication Date Title
TR200001203T2 (en) New compounds
YU97202A (en) Combinations and compositions which interfere with vegf/vegf and angiopoietin/tie receptor function and their use (ii)
EP1302542A4 (en) Novel physiologically active peptide and use thereof
MY176938A (en) 3,5-disubstituted and 3,5,7-trisubstituted-3h-oxazolo and 3h-thiazolo[4,5-d] pyrimidin-2-one compounds and prodrugs thereof
WO2003030927A3 (en) Use of thymulin-like peptides for making pain-relieving medicines
AP2034A (en) Oxidized proteins, their biological activity, and therapeutic and diagnostic measures, which are derived from the active mechanism, from the use of these proteins or from the inhibition thereof.
TR200103638T2 (en) IL-8 Receptor antagonists
HK1061209A1 (en) Use of the long pentraxin ptx3 for the treatment of diseases caused by an altered activation of the growth factor fgf-2
IL156069A0 (en) Use of a substance which binds to sarp-1 receptor or influences the activity of endogenous sarp-1 in scleroderma
NO995692D0 (en) Novel BPC peptide salts with organ protective activity, the method of their preparation and their use
IL174134A0 (en) Use of a protein in the preparation of a medicament for treatment of fibrotic diseases
ATE554393T1 (en) DIAGNOSTICS AND THERAPEUTICS FOR DISEASES ASSOCIATED WITH ADIPONECTIN RECEPTOR 2 (ADIPOR2).
HUP0100612A2 (en) Method of screening therapeutic agents
ES2191776T3 (en) COMPOSITIONS CONTAINING BISMUTO AND ONE OR MORE ANTIMICROBIAL AGENTS, FOR THE PREVENTION AND TREATMENT OF GASTROINTESTINAL DISORDERS.
DK1196439T3 (en) Compounds exhibiting an antibiotic activity
BR0014831A (en) Therapeutic drug for refractory lesions, comprising a substance with human leukocyte elastase inhibitory activity
IL156144A0 (en) Novel therapeutic use of a thienylcyclohexylamine derivative
ATE291435T1 (en) CHLORIZOXAZONE FOR THE TREATMENT OF PSORIASIS
ES2173334T3 (en) COMPOSITIONS CONTAINING BISMUTO, FOR THE PREVENTION AND TREATMENT OF GASTROINTESTINAL DISORDERS.
FR2846658B1 (en) PEPTIDES FOR THE PREVENTION, DIAGNOSIS AND TREATMENT OF ANIMAL AND / OR HUMAN LEPTOSPIROSIS.
PT1233748E (en) ASSOCIATION OF RETINAL AND ALDEIDS WITH ANTIFUNGAL ACTIVITY
WO2004005346A3 (en) Human nuclear hormone receptor
FR2759586B1 (en) ANTI-CANCER TYPE DRUG COMPRISING AT LEAST AS THE ACTIVE INGREDIENT OF 1-ALPHA HYDROXYCALCIFEROL OR ALFACALCIDOL
ATE382342T1 (en) POMOLIC ACID FOR THE TREATMENT OF MULTIPLE RESISTANT TUMORS
EP1328662A4 (en) Flea peritrophin nucleic acid molecules, proteins and uses thereof